KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Emergent BioSolutions (EBS) Operating Margin (2016 - 2026)

Emergent BioSolutions has reported Operating Margin over the past 16 years, most recently at 6.73% for Q1 2026.

  • For Q1 2026, Operating Margin fell 1573.0% year-over-year to 6.73%; the TTM value through Mar 2026 reached 8.97%, up 2193.0%, while the annual FY2025 figure was 13.47%, 2389.0% up from the prior year.
  • Operating Margin for Q1 2026 was 6.73% at Emergent BioSolutions, up from 18.76% in the prior quarter.
  • Over five years, Operating Margin peaked at 33.1% in Q3 2025 and troughed at 407.0% in Q2 2024.
  • A 5-year average of 39.92% and a median of 15.84% in 2023 define the central range for Operating Margin.
  • Biggest five-year swings in Operating Margin: crashed -32032bps in 2024 and later soared 40814bps in 2025.
  • Year by year, Operating Margin stood at 16.75% in 2022, then increased by 5bps to 15.84% in 2023, then skyrocketed by 69bps to 4.88% in 2024, then plummeted by -285bps to 18.76% in 2025, then skyrocketed by 136bps to 6.73% in 2026.
  • Business Quant data shows Operating Margin for EBS at 6.73% in Q1 2026, 18.76% in Q4 2025, and 33.1% in Q3 2025.